$CGNT (Cogentix Medical, Inc.)

$CGNT {{ '2016-09-08T12:11:55+0000' | timeago}} • Announcement

$CGNT said upon closing of the proposed transactions, there would be about 60.3MM shares outstanding of which Pell would own about 33% and Accelmed would own about 27%. Current debt and accrued interest outstanding of $29.5MM would be eliminated and $CGNT would have about $28MM of cash and marketable securities.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$PG {{ '2017-10-10T16:14:25+0000' | timeago}} • Announcement

$PG's shareholders have voted to elect all 11 of its highly qualified Directors to its Board. Nelson Peltz of Trian was not elected to the Board. This is based on a preliminary vote count provided by its proxy solicitors following its 2017 Annual Meeting.

$EBS {{ '2017-10-03T13:27:49+0000' | timeago}} • Announcement

Life sciences firm $EBS completed the acquisition of raxibacumab, an FDA-approved human monoclonal antibody for the treatment of inhalational anthrax, from $GSK. The company plans a $130MM contract with the Biomedical Advanced Research and Development Authority to supply the product to the US Strategic National Stockpile through November 2019.

$VVV {{ '2017-10-02T21:27:08+0000' | timeago}} • Announcement

$VVV has completed the acquisition of 56 Valvoline Instant Oil ChangeSM (VIOC) franchise service centers from Henley Bluewater LLC. Following the acquisition, the company has a network of 439 company-owned locations.

$AGN {{ '2017-10-02T17:04:07+0000' | timeago}} • Announcement

FDA accepts to do a priority review of $AGN's antibiotic drug Avycaz. The supplemental New Drug Application (sNDA) filed by Allergan seeks to expand the usage of Avycaz for the treatment of patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. The FDA is expected to take action on the filing in 1Q18.

$PG {{ '2017-10-02T13:29:58+0000' | timeago}} • Announcement

$PG responded to the report issued by Institutional Shareholder Services regarding the election of directors to the P&G Board at its Annual Meeting of Shareholders to be held on Oct. 10, 2017. The Board strongly recommend shareholders vote "For" all of its highly qualified directors on the Blue proxy card.

$VVV {{ '2017-09-29T11:54:15+0000' | timeago}} • Announcement

Supplier of premium branded lubricants and automotive services $VVV said that William Wulfsohn, who served as the company's founding chairman during its initial year as a public company, will step down from his position as Chairman of the Board as of Sept. 30, 2017.

$LLY {{ '2017-09-28T21:06:48+0000' | timeago}} • Announcement

FDA approves $LLY's breast cancer drug Verzenio (abemaciclib), which will compete with $PFE's Ibrance and $NVS' Kisqali drugs. Verzenio works by blocking certain molecules involved in promoting the growth of cancer cells. The National Cancer Institute estimated that approximately 252,710 women will be diagnosed with breast cancer this year.

$PFE {{ '2017-09-27T12:44:41+0000' | timeago}} • Announcement

$PFE declared 4Q17 dividend of $0.32 per share, payable Dec. 1, 2017, to shareholders of record at the close of business on Nov. 10, 2017. This cash dividend will be the 316th consecutive quarterly dividend paid by the company.

$PFE {{ '2017-09-27T12:19:24+0000' | timeago}} • Announcement

$PFE receives approval for BAVENCIO to treat Merkel cell carcinoma (MCC), a rare type of skin cancer, in Japan. This is the first-ever treatment indicated for curatively unresectable MCC and first anti-PD-L1 to be available in Japan.

$INFO {{ '2017-09-26T13:19:34+0000' | timeago}} • Announcement

$INFO, a provider of analytics and solutions to enterprises, has acquired majority stake in automotiveMastermind Inc., a technology company in the automotive industry, for about $392MM. IHS will acquire the remaining 22% of automotiveMastermind's stock over the next five years, based on valuation tied to underlying business performance.

$INFO {{ '2017-09-26T12:01:00+0000' | timeago}} • Announcement

$INFO announced the acquisition of about 78% of automotiveMastermind Inc. for about $392MM, which can increase up to $435MM tied to underlying business performance. $INFO will buy the balance 22% over the next 5 years based on valuation tied to underlying business performance.

$INFO {{ '2017-09-26T10:58:37+0000' | timeago}} • Announcement

$INFO now expects FY17 revenue to be at the high end of $3.49-3.56Bil, including total organic growth of 3-4%, and adjusted EPS trending at the mid-point of $2.02-2.08. The company now predicts adjusted EBITDA to trend at the low- to mid-point of $1.375-1.4Bil.

$INFO {{ '2017-09-26T10:56:15+0000' | timeago}} • Announcement

$INFO swung to profit in 3Q17 from a loss last year, on organic revenue growth and margin expansion, despite Jerre Stead's transition out of the chairman and CEO role. Net income was $147.1MM or $0.35 per share compared to a loss of $32MM or $0.09 per share last year. Revenue jumped 25% to $904.7MM. Adjusted EPS increased 27% to $0.57.

$AGN {{ '2017-09-25T15:26:35+0000' | timeago}} • Announcement

$AGN CFO Tessa Hilado has decided to retire from the company. Allergan has initiated a search to fill the position. Hilado, who joined the company in Dec 2014, will continue in her current role until a successor is named to ensure a smooth transition.

$AGN {{ '2017-09-25T12:23:08+0000' | timeago}} • Announcement

$AGN has authorized a new $2Bil share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend annually. The company also affirmed its 3Q17 revenue projection, which was issued on Aug 3, 2017.

$AGN {{ '2017-09-22T21:53:16+0000' | timeago}} • Announcement

$AGN received a Refusal to File letter from the US FDA on its Supplemental New Drug Application (sNDA) for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral antipsychotic approved in the US to treat schizophrenia. The FDA said the sNDA was not sufficient to permit a substantive review.

$PG {{ '2017-09-22T17:25:15+0000' | timeago}} • Announcement

$PG issued statement in response to the report issued by Glass Lewis. The company reiterated that significant transformation is delivering shareholder value. The Board has done its homework and concluded that Nelson Peltz is Not the right director. $PG urged shareholders to vote "For" all of its directors on the Blue proxy card.

Recent Transcripts

INFO (IHS Markit Ltd.)
Tuesday, September 26 2017 - 12:00pm
APPS (Digital Turbine, Inc.)
Monday, August 7 2017 - 8:30pm
VER (VEREIT, Inc.)
Thursday, August 3 2017 - 5:00pm
AAC (AAC Holdings, Inc.)
Thursday, August 3 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
FIT (Fitbit Inc.)
Wednesday, August 2 2017 - 9:00pm
VVV (Valvoline Inc.)
Wednesday, August 2 2017 - 3:00pm
AJX (Great Ajax Corp)
Tuesday, August 1 2017 - 9:00pm
CGNT (Cogentix Medical, Inc.)
Tuesday, August 1 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
ITGR (Integer Holdings Corporation)
Thursday, July 27 2017 - 9:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
GSK (GlaxoSmithKline plc)
Wednesday, July 26 2017 - 1:00pm
NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VER (VEREIT, Inc.)
Thursday, May 4 2017 - 5:00pm
AAC (AAC Holdings, Inc.)
Thursday, May 4 2017 - 1:00pm
FIT (Fitbit Inc.)
Wednesday, May 3 2017 - 9:00pm
AJX (Great Ajax Corp)
Tuesday, May 2 2017 - 9:00pm
CGNT (Cogentix Medical, Inc.)
Tuesday, May 2 2017 - 8:30pm

AlphaGraphics you may like